GlassScriptPhysician profile
Anjum Tanwir
NPI 1144320128
$11,574.34
in general payments reported to CMS, 2019-2025
43 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,617 · 2020: $1,196 · 2021: $1,882 · 2022: $2,174 · 2023: $1,967 · 2024: $914 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,258 · Travel and Lodging: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.85 |
| Travel and Lodging | $446.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,081.19 | 2019-2025 | Diamondback Peripheral, Supera, Esprit |
| Cardiovascular Systems INC. | $1,373.36 | 2019-2022 | |
| Cvrx, INC. | $966.92 | 2020-2024 | Barostim Neo System |
| Cordis US Corp. | $760.06 | 2021-2023 | Brite Tip Radianz, S.M.A.R.T. Control, Saber |
| Abiomed | $716.29 | 2019-2025 | Impella |
| Shockwave Medical, INC | $611.02 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Amgen INC. | $582.91 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $582.61 | 2019-2022 | |
| Philips North America LLC | $482.29 | 2022-2025 | Laser Serv and Other Undivided, IV Other |
| Novartis Pharmaceuticals Corporation | $445.81 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $304.13 | 2019-2021 | |
| Lilly USA, LLC | $231.39 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $208.83 | 2019-2023 | Spravato, Xarelto |
| Penumbra, INC. | $207.84 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $197.43 | 2019-2025 | Camzyos, Eliquis |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjum Tanwir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.